BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

Despite the high-profile nature of the patent dispute between Illumina and Chinese competitor BGI Genomics, two of the largest players in next-generation sequencing, there is no reason to believe it will become embroiled in the...
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BC Extra | Jul 24, 2019
Company News

July 24 Management tracks: GSK, Goldman Sachs, Ziopharm and Alkahest

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Wednesday that it has appointed Jonathan Symonds as non-executive chairman to succeed Philip Hampton, effective Sept. 1. Symonds is deputy group chairman at HSBC and has served as CFO Novartis...
BC Extra | Apr 6, 2019
Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
BioCentury | Oct 19, 2018
Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...
BC Innovations | Oct 11, 2018
Strategy

Border security for China’s genomes

China’s policies on sharing genomic data have so far produced cumbersome but manageable hurdles for cross-border clinical trials and translational research. But the explosive growth of its genomics industry, and the backdrop of rising political...
BC Extra | Jun 28, 2018
Politics & Policy

Broader CFIUS jurisdiction may have implications for biotech

President Donald Trump said Wednesday he plans to use the Committee on Foreign Investment in the United States (CFIUS) to protect U.S. innovation, citing a House of Representatives bill that seeks to expand the agency's...
BC Extra | Aug 18, 2017
Preclinical News

Papers describe liquid biopsy next-generation sequencing

At least five recently published studies have shown the utility of liquid-based biopsies in cancer detection, suggesting that liquid biopsy next-generation sequencing (NGS) could replace traditional detection methods of PCR and tumor biopsies. In addition,...
BC Innovations | Aug 18, 2017
Translation in Brief

Next-generation growth spurt

A milestone FDA approval could signal next-generation sequencing tests are on the verge of becoming established players in cancer diagnostics. A series of papers published this week highlights further advances in NGS technology, but the...
Items per page:
1 - 10 of 112
BioCentury | Jun 26, 2020
Politics, Policy & Law

Illumina, BGI litigation not yet at risk of getting drawn into U.S.-China dispute

Despite the high-profile nature of the patent dispute between Illumina and Chinese competitor BGI Genomics, two of the largest players in next-generation sequencing, there is no reason to believe it will become embroiled in the...
BioCentury | Jun 17, 2020
Product Development

June 16 Quick Takes: Takeda out-licenses neurology pipeline to Neurocrine; plus Illumina challenge blocks BGI, FDA approves a pair of firsts and more

Takeda receives $120M up front for seven neurology therapies  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) an exclusive, worldwide license to seven neurology programs: three mood disorder therapies that have completed...
BioCentury | Feb 28, 2020
Product Development

Feb. 27 Quick Takes: FDA approves Biohaven’s migraine therapy, plus Acacia, Zogenix, Ultragenyx-Kyowa, GSK, Illumina-BGI

Migraine drug marks Biohaven’s first FDA approval Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) announced after market close that FDA approved NURTEC ODT rimegepant as an acute treatment for migraine, marking the company’s first U.S. approval....
BC Extra | Jul 24, 2019
Company News

July 24 Management tracks: GSK, Goldman Sachs, Ziopharm and Alkahest

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) announced Wednesday that it has appointed Jonathan Symonds as non-executive chairman to succeed Philip Hampton, effective Sept. 1. Symonds is deputy group chairman at HSBC and has served as CFO Novartis...
BC Extra | Apr 6, 2019
Politics & Policy

CFIUS drawing line in sand on personal data

The Trump administration has further reinforced which kinds of life science investments will be off limits for foreign investors, as reports emerge that CFIUS is compelling two more Chinese firms to relinquish control over companies...
BioCentury | Oct 19, 2018
Politics, Policy & Law

CFIUS waiting game

Biotech and its investors must wait to find out how much of the industry will be caught up in the CFIUS dragnet of foreign investment in American companies, but the U.S. Treasury has given itself...
BC Innovations | Oct 11, 2018
Strategy

Border security for China’s genomes

China’s policies on sharing genomic data have so far produced cumbersome but manageable hurdles for cross-border clinical trials and translational research. But the explosive growth of its genomics industry, and the backdrop of rising political...
BC Extra | Jun 28, 2018
Politics & Policy

Broader CFIUS jurisdiction may have implications for biotech

President Donald Trump said Wednesday he plans to use the Committee on Foreign Investment in the United States (CFIUS) to protect U.S. innovation, citing a House of Representatives bill that seeks to expand the agency's...
BC Extra | Aug 18, 2017
Preclinical News

Papers describe liquid biopsy next-generation sequencing

At least five recently published studies have shown the utility of liquid-based biopsies in cancer detection, suggesting that liquid biopsy next-generation sequencing (NGS) could replace traditional detection methods of PCR and tumor biopsies. In addition,...
BC Innovations | Aug 18, 2017
Translation in Brief

Next-generation growth spurt

A milestone FDA approval could signal next-generation sequencing tests are on the verge of becoming established players in cancer diagnostics. A series of papers published this week highlights further advances in NGS technology, but the...
Items per page:
1 - 10 of 112